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Abstract
Glioblastoma is the most lethal brain tumor and its pathogenesis remains incompletely understood. KDM4C is a
histone H3K9 demethylase that contributes to epigenetic regulation of both oncogene and tumor suppressor genes
and is often overexpressed in human tumors, including glioblastoma. However, KDM4C’s roles in glioblastoma and the
underlying molecular mechanisms remain unclear. Here, we show that KDM4C knockdown significantly represses
proliferation and tumorigenesis of glioblastoma cells in vitro and in vivo that are rescued by overexpressing wild-type
KDM4C but not a catalytic dead mutant. KDM4C protein expression is upregulated in glioblastoma, and its expression
correlates with c-Myc expression. KDM4C also binds to the c-Myc promoter and induces c-Myc expression.
Importantly, KDM4C suppresses the pro-apoptotic functions of p53 by demethylating p53K372me1, which is pivotal
for the stability of chromatin-bound p53. Conversely, depletion or inhibition of KDM4C promotes p53 target gene
expression and induces apoptosis in glioblastoma. KDM4C may serve as an oncogene through the dual functions of
inactivation of p53 and activation of c-Myc in glioblastoma. Our study demonstrates KDM4C inhibition as a promising
therapeutic strategy for targeting glioblastoma.
Introduction
Glioblastoma is the most common primary brain can-
cer. Glioblastoma remains one of the most malignant
diseases with limited treatment options and leads to
lethality within two years of diagnosis1. Although genetic,
environmental, bacterial infection, and several other fac-
tors are known to be involved in gliomagenesis, the
underlying molecular mechanism remains poorly under-
stood. Typically, glioblastoma has the following char-
acteristics: rapid disease progression, high metastasis,
poor prognosis, and high mortality rates2. In addition, it is
difficult to improve the glioblastoma response to therapies
targeting profoundly altered signaling pathways due to the
intratumoral heterogeneity and the presence of cancer
stem cells. Therefore, there exists an urgent and critical
need to define the pathogenesis of glioblastoma in a better
manner, to identify useful biomarkers, and to explore
novel alternative therapeutic targets.
Mutation and abnormal expression of different histone
demethylases (KDMs) have often been observed in human
diseases, including cancers3,4, making them potential ther-
apeutic targets. Although the roles of specific KDM in a
given cancer type remain to be elucidated, the KDM4 family
members are largely considered as oncogenes. KDM4A-D
are histone H3 lysine 9 (H3K9) specific demethylases5,6. The
oncogenic properties of the KDM4 family could arise from
activating their targets by binding to their promoters and
removing trimethyl (me3) and dimethyl (me2) groups from
H3K9. KDM4A-C possesses a similar protein structure,
including the jumonji domain (JmjN and JmjC), a tandem
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plant homeodomain (PHD), and a tandem Tudor domain,
whereas KDM4D lacks the PHD and Tudor domains, which
function as a histone reader domain6.
Although the role of KDM4C in glioblastoma is not well
investigated, KDM4C has been reported to be an onco-
gene in other cancers. Among the KDM4s, the KDM4C
gene, which is located on chromosome 9p24, is often
amplified or overexpressed in various hematological and
solid cancers, including lymphoma, breast cancer, pros-
tate cancer, esophageal squamous cell carcinoma, sarco-
matoid lung carcinoma, and medulloblastoma5,7–15. In
normal and some cancer cells, KDM4C regulates cell
proliferation by activating the target genes that are
involved in cell signaling, cell cycle, and translation.
Consistently, the depletion of KDM4C from cancer cells
leads to the attenuation of cell growth10,16–18, whereas
overexpression of KDM4C in human nontransformed
mammary epithelial cells results in phenotypic changes of
neoplastic transformation, including growth factor- and
anchorage-independent proliferation10. The involvement
of KDM4C in tumorigenesis has been further supported
by demonstrating that KDM4C expression requires
colonosphere formation in colon cancer cells through
interaction with β-catenin19. Together, these studies
indicate that KDM4C promotes tumorigenesis. Therefore,
this enzyme has recently become an attractive drug target
for cancer therapeutics20,21. However, till date, no potent
and specific small-molecule inhibitor of the KDM4 family,
including KDM4C, has been developed. Moreover, the
expression and function of KDM4C and its mechanisms
of action in glioblastoma are largely unknown.
In the present, we investigated the function of KDM4C
in glioblastoma development and progression. We iden-
tified KDM4C as an essential factor required for the
proliferation of glioblastoma and demonstrated that c-
Myc and p53 are critical downstream effectors of KDM4C
in this process. KDM4C positively correlated with c-Myc
expression in human glioblastoma cell lines and tissues.
KDM4C directly induced the expression of c-Myc. In
addition, we revealed that KDM4C is a novel lysine
demethylase for a tumor suppressor p53. KDM4C inter-
acted with and demethylated p53 monomethylation at
lysine 372 (p53K372me1), resulting in decreased
p53 stability. Thus, the pro-apoptotic function of p53 was
compromised in the presence of KDM4C. Our findings
reveal that KDM4C promotes glioblastoma survival by
inactivating the c-Myc-mediated p53 pathway and con-




SD70 was purchased from Xcess Biosciences (San Diego,
CA, USA).
Cell lines and culture
Human glioblastoma cell lines [wild-type (wt) p53; U87
(HTB-14) and A172 (CRL-1620), and mutant (mt) p53;
LN229 (CRL-2611), SNB19 (CRL-2219), and T98G (CRL-
1690)] were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). U343 (wt p53;
300365) and U251 (mt p53; 300385) cells were purchased
from CLS Cell Lines Service GmbH (Eppelheim, Ger-
many). LN215 (mt p53) cells were a kind gift from Dr.
Erwin G. Van Meir (Emory University, Atlanta, Georgia,
USA) and D54 (wt p53) cells from Dr. Andres Gutiérrez
(Bringham, AL, USA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Gaithersburg,
MD, USA) containing 10% fetal bovine serum (FBS), 100
units/ml penicillin, and 100 µg/ml streptomycin in a
humidified atmosphere of 5% CO2 and 95% air at 37 °C.
ATCC and CLS uses karyotyping, morphology, and PCR-
based approaches to confirm the identity of cell lines.
Lentiviral shRNA knockdown
The lentiviral shRNA sets for KDM4C were purchased
from Sigma-Aldrich (St. Louis, MO, USA) following the
procedure of Addgene (Watertown, MA, USA). The fol-





GGCTTTTT (#2, NM_015061.1-768s1c1, TRCN00000
22054), and CCGGCAGCGGGTAGGGCGATAATTTC
TCGAGAAATTATCGCCCTACCCGCTGTTTTTG (#3,
NM_015061.2-4140s21c1, TRCN0000257272). The non-
targeted control sequence (shCtrl NT) is GCAAGCT
GACCCTGAAGTTCATTCAAGAGATGAACTTCAGG
GTCAGCTTGCTTTTTG. To generate respective lenti-
virus, shRNA vector (pLKO.1) and packaging plasmid
(psPAX2) and enveloping plasmid (pMD2.G) were used to
cotransfect HEK293T cells as previously described22.
Supernatants containing lentivirus were collected 48 and
72 h after transfection. Then, cells were infected three
times every 12 h with lentivirus. Subsequently, cells were
selected for 48 h in 2 μg/ml puromycin, to select the cells
carrying the respective antibiotic resistance gene.
Establishment of U87 Tet-On doxycycline-inducible
shKDM4C cells
The Tet-on 3G doxycycline-inducible expression sys-
tem (#631354, Takara Bio USA) was used to induce the
expression of shKDM4C inserted under the TRE3G pro-
moter in U87 cells according to the manufacturer’s pro-
tocol. U87 cells were treated with lentivirus-Tet3G
(pLVX-EF1a-Tet3G regulator vector) and selected with
G418 (2 mg/ml) to generate U87-Tet3G cells. Next, U87-
Tet3G cells were stably transfected with pLVX-TRE3G-
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shKDM4C (shKDM4C sequences; #1, NM_015061.1-
1702s1c1, TRCN0000022058 and #2, NM_015061.1-
768s1c1, TRCN0000022054) response vector and selected
with puromycin (2 μg/ml) for Tet-On inducible
shKDM4C cells. The expression of KDM4C was con-
firmed in media containing doxycycline (Dox; 100 μg/ml).
Small interfering RNA (siRNA) transfection
For siRNA transfection, we purchased control luciferase
and KDM4C siRNA from ST Pharm Oligocenter (Seoul,
Republic of Korea). The siRNA sequence targeted KDM4C:
sense, 5′-GCAGCUGAGCAAGAGUAUA(dTdT)-3′ and
anti-sense, 5′-UAUACUCUUGCUCAGCUGC(dTdT)-3′
and siRNA sequences targeted luciferase control: 5′-UC
GAAGUACUCAGCGUAAG(dTdT)-3′. For transfection,
cells were grown to 80% confluence and then transfected
with siRNA (100 nM) RNAiMAX Lipofectamine agent
(ThermoFisher, Waltham, MA, USA) according to the
manufacturer’s instructions. Finally, cells were incubated
with the siRNA mixture for 24 h and changed the medium
with fresh serum-free medium.
Cell growth and viability assay
Cell growth and viability were determined using the
CCK8 assay [Cell Counting Kit (CCK)-8 kit, Dojindo
Molecular Technologies, Inc., Kumamoto, Japan] as
described previously23. Cells were seeded at a density of
0.5–1 × 103 cells in 200 μl medium in 96-well plates in
triplicate. After overnight incubation, SD70 was added
to the cells at the indicated concentrations for 72 h at
37 °C. Twenty microliters of WST-8 was added to each
well for the final 3 h, and absorbance was measured at
450 nm using a microplate reader (TECAN, Mannedorf,
Switzerland). For cell growth analysis, a standard curve
was generated using solutions of known cell counts
(0.5 × 103, 1 × 103, 2 × 103, 3 × 103, 4 × 103, 5 × 103, 6 ×
103, 7 × 103, and 8 × 103 cells/well). Cell counts were
indirectly estimated from absorbance measurements
relative to the obtained standard curve. The absorbance
of the negative control without DMSO was used to
normalize data at each time interval. For cell viability
analysis, the cell viable percentage was calculated rela-
tive to the negative control group. Results were statis-
tically analyzed by Prism 5 (GraphPad Inc., San Diego,
CA, USA). IC50 and GI50 values were calculated by
nonlinear regression model.
Proliferation assay
The effect of KDM4C knockdown on U87 and U251 cell
proliferation was monitored in real-time using the Incu-
CyteTM Live-Cell Imaging System (Essen BioScience,
Hertfordshire, United Kingdom) as described pre-
viously22. A total of 500 cells expressing KDM4C shRNA
were seeded in 96-well plates at a minimum of six
replicates. The next day, automated phase-contrast ima-
ges were obtained using IncuCyteTM microscope. Indi-
vidual images were processed using an embedded
contrast-based confluence algorithm that converts the
monolayer confluence for each image at each time point
to percentage. Multiple images were collected for each
well and obtained a statistical measurement of confluence.
Liquid colony formation assay
In total, 500 cells were seeded into 6 well plates and
cultured for 24 h. Cells were then treated with shKDM4C
or various doses of SD70 in triplicate. Drugs were
removed at 96-h post-treatment, and cells were cultured
until they reached optimal densities. Colony formation
was visualized by staining the plates with 0.05% crystal
violet (Sigma) for >1 h according to the manufacturer’s
instruction. Integrated density was determined using the
NIH ImageJ software.
Apoptosis assay
Apoptosis was analyzed using the Annexin V/propi-
dium iodide (PI) double-staining method according to the
manufacturer’s instructions (Annexin V-FITC Apoptosis
Detection Kit; BD Biosciences, Franklin Lakes, NJ, USA)
as previously described24. After treatments, the cells were
stained for 30 min at room temperature with 0.5 mg/ml
Annexin V in binding buffer (10 mM HEPES free acid,
0.14M NaCl, and 2.5 mM CaCl2). Next, 5 mg/ml of PI was
added and incubated for 15 min at room temperature.
The cells were assessed using a flow cytometer and BD
FACSDiva software version 7 (both from BD Biosciences).
Western blot analysis and co-immunoprecipitation (Co-IP)
assay
As indicated, cells were grown, treated, collected, lysed,
and separated by SDS-PAGE; western blotting was also
performed as described previously25. Immunoprecipita-
tion was achieved by incubating the cell lysates with anti-
p53 monoclonal antibody (sc-126, Santa Cruz Bio-
technology, Dallas, TX, USA) at 4 °C overnight with
rotation. Protein A/G agarose slurry was added to the
reaction mixture for 3 h. Then, the precipitated proteins
were detected by immunoblotting with the corresponding
antibodies. The blots were semi-quantified using the
FusionCapt software version 16.08a (Vilber Lourmat Sté,
Collégien, France). Protein expression levels were quan-
tified against α-tubulin or GAPDH, and control levels
were set at 1. The sources of the primary antibodies are
listed in Supplementary Table 1.
Luciferase reporter assay
U87 cells were seeded at 2 × 104 into 24-well plates and
allowed to reach ~70% confluence. Cells were transiently
transfected with 300 ng of luciferase reporter constructs
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driven by the human p21 or Bax promoter using iN-fect
(iNtRON Biotechnology, Seongnam, Republic of Korea).
In addition, 50 ng of empty pcDNA3.1 or pcDNA3-p53
vectors and 300 ng of empty pCMV-HA or pCMV-HA-
KDM4C vectors were cotransfected into U87 cells. After
24 h of transfection, the cell lysates were analyzed with a
Luciferase Reporter Assay kit (Promega, Madison, Wis-
consin, USA), according to the manufacturer’s instruc-
tions as previously described23. In all experiments,
luciferase activity was analyzed at equal amounts of pro-
tein. Relative luciferase activity was measured by a
microplate reader (TECAN, Maennedorf, Switzerland).
All experiments were performed at least three times. The
DNA constructs are listed in Supplementary Table 2.
RNA isolation and quantitative reverse transcriptase-PCR
(qRT-PCR)
RNA isolation, cDNA synthesis, and quantitative RT-
PCR were performed according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA) as pre-
viously described23. qRT-PCR was performed with the
Applied Biosystems 7500 System (Applied Biosystems,
Foster City, CA, USA) using SYBR green qPCR master
mix and gene-specific primers. mRNA expression levels
were normalized to GAPDH mRNA levels. Fold expres-
sion determination, gene-to-GAPDH ratios were deter-
mined by using the 2−ΔΔCt method. The primer sequences
are listed in Supplementary Table 3.
Chromatin immunoprecipitation (ChIP) assay
U87 cells were cross-linked using 1% formaldehyde for
10min at room temperature. Nuclear extracts were pre-
pared, and chromatin was sonicated to generate
200–1000 bp DNA fragments. For each assay, 40 μg DNA
was immunoprecipitated by control IgG or KDM4C
(ab13440, abcam), p53 (sc-126, Santa Cruz Biotechnol-
ogy), histone H3K9me3 (ab8898, abcam), and histone
H3K4me3 (07-473, Millipore) antibodies with protein A
beads. The DNA-protein crosslinks were reversed by
incubating at 65 °C for 4 h. Then, DNA was extracted
using phenol and chloroform, followed by ethanol pre-
cipitation. Recovered and purified chromatin fragments
were subjected to qPCR. IgG control experiments were
performed for all ChIPs and incorporated into the IP/
Input (10%) by presenting the results as (IP-IgG)/(Input-
IgG). Corresponding primers: c-Myc P0 promoter, for-
ward 5′-CCCCCGAATTGTTTTCTCTT-3′ and reverse
5′-TCTCATCCTTGGTCCCTCAC-3′, c-Myc P1 pro-
moter, forward 5′-GAGGGATCGCGCTGAGTA-3′ and
reverse 5′-CGGCTCTTCCACCCTAGC-3′, c-Myc P2
promoter, forward 5′-GCCGCATCCACGAAACTT-3′
and reverse 5′-TCCCCAAATGGGCAGAAT-3′, c-Myc
P3 promoter, forward 5′-CGGTGCAGCCGTATTTCTA
C-3′ and reverse 5′-CAGCAGCTCGAATTTCTTCC-3′,
PUMA p53 binding promoter, forward 5′-ACAGCG
CCTGGGTCCTCCTT-3′ and reverse 5′-GGACAAG
TCAGGACTTGCAG-3′.
Animal experiments
All animal experiments were approved by the Institutional
Review Board of the Yonsei University College of Medicine
and were performed in specific pathogen-free facilities
according to the university’s guidelines for the Care and Use
of Laboratory Animals. Mice were inoculated subcutaneously
with 2 × 106 stable TetOn-non-target (NT), TetOn-
shKDM4C-1, and TetOn-shKDM4C-2 U87 cells into each
flank under 100 µL of saline/zoletil/rompun (7:1:1) anesthe-
sia. Randomized mice (n= 6 per group) were treated with
doxycycline (Duchefa, Netherlands) after 13 days of tumor
implantation. Doxycycline was administered to tumor-
bearing animals orally, three times a week for 2 weeks at a
dose of 10mg/kg. Tumor sizes were measured every 3 to
4 days from palpable tumor formation until termination
using calipers. Tumor volume was calculated using the fol-
lowing formula: length ×width 2 × 0.5236. Mice were sacri-
ficed in a 7.5% CO2 chamber, and the tumors were harvested
for immunohistochemistry and other experiments.
Immunohistochemistry (IHC) assay
For IHC assays, paraffin-embedded tissue sections were
incubated with KDM4C (1:100, ab13440, abcam) and c-
Myc antibodies (1:100, sc-40, Santa Cruz Biotechnology)
at 4 °C overnight. SignalStain Boost IHC Detection
Reagent (horseradish peroxidase, mouse) (Cell Signaling
Technologies, Danvers, MA, USA) was added at room
temperature for 10–30 min, according to the manu-
facturer’s instructions as previously described23. For
visualization, DAB Horseradish Peroxidase Color Devel-
opment Kit was used. For tissue counterstain, hematox-
ylin was used.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism software (version 5.0, GraphPad Software). All data
are presented as the mean ± standard deviation (SD) of
more than three independent experiments. Statistical
differences were determined by Student’s t-test, one-way
analysis of variance (ANOVA) with post hoc analysis
using Tukey’s multiple comparison test, and Pearson
correlation coefficient tests. P < 0.05 was considered to
indicate a statistically significant difference.
Results
KDM4C is upregulated in glioblastoma
Elevated KDM4 expression has been reported in various
cancers and indicates poor prognosis in several cancer
cases26. However, the role of KDM4 in glioblastoma
tumorigenesis has not yet been well defined. To determine
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the expression level of KDM4 proteins in glioblastoma, we
conducted mRNA expression profiling on glioblastoma
microarray data from Gene Expression Omnibus (GEO)
dataset (GSE90886) (Fig. S1). Among the 29 KDMs,
KDM4C expression was the only one significantly higher in
glioblastoma tissues compared to control ones. We next
analyzed the expression of KDM4 proteins in the following
9 different glioblastoma cell lines: A172, D54, U343, U87,
LN215, LN229, U251, SNB19, and T98G. Immunoblot
analysis revealed that KDM4C and KDM4D protein levels
were highly expressed in most of the glioblastoma cell lines,
whereas the protein levels of KDM4A and KDM4B were
very low or not detected (Fig. S2). Our results demonstrated
that KDM4C was highly expressed in glioblastoma cells and
tissues.
KDM4C is essential for glioblastoma proliferation
Based on the overexpression of KDM4C in glioblastoma,
we speculated that KDM4C might regulate the prolifera-
tion of glioblastoma cells. To address the importance of
KDM4C in glioblastoma cell growth and viability, we
downregulated KDM4C in U87 and U251 glioblastoma
cells using siRNAs or shRNA (Fig. 1A, D and Fig. S3A, D).
Next, the proliferation kinetics of glioblastoma cells were
assessed using IncuCyte and CCK8 assay. The growth
curve revealed that knockdown of KDM4C in glioblastoma
cells resulted in significant short-term (Fig. 1B and Fig.
S3B, E) and long-term (Fig. 1E, F) growth inhibition
compared to that in the control groups of the two cell
lines. In addition, the CCK8 assay confirmed that the
downregulation of KDM4C induced a significant decrease
in cell viability (Fig. 1C and Fig. S3C, F). Similar results
were also observed in other glioblastoma A172 cells (Fig.
S3G‒I). Furthermore, we detected a pronounced inhibi-
tory effect of KDM4C silencing and inhibition by SD70, a
KDM4C-selective inhibitor27 on cell proliferation through
the colony formation assay (Fig. 1G and Fig. S5). Notably,
KDM4C knockdown resulted in increased global levels of
H3K9me3 and H3K9me1, whereas there was a decline in
the global levels of H3K9me2 (Fig. 2A). The above data
were also confirmed by the treatment of SD70 in the
glioblastoma cells (Fig. S4A), wherein KDM4C inhibition
decreased the growth and viability of various glioblastoma
cells both time- and dose-dependently (Fig. S4C, D and
Fig. S6). Furthermore, the inhibitory effect of shKDM4C
on the cell growth and viability was rescued by wt KDM4C
but not by demethylase dead mutant KDM4C H190A,
suggesting that the activity of KDM4C is essential for
glioblastoma cell proliferation and survival (Fig. S7B, C).
Depletion of KDM4C induces apoptosis in glioblastoma
To gain molecular insights into the mechanism by
which KDM4C regulates glioblastoma growth and viabi-
lity, we investigated the expression of key cell cycle and
apoptotic regulatory proteins using immunoblot assays.
Interestingly, we observed that KDM4C knockdown
reduced expression of the cyclins (cyclin A1, D1, D2, and
E2) and cyclin-dependent kinases (CDKs) (CDK2, CDK4,
and CDK6) and induced the CDK inhibitor p21 (Fig. S8).
In addition, knockdown of KDM4C induced the apoptosis
of glioblastoma cells, as demonstrated by the increase in
annexin V/PI-positive cells and upregulation of cleaved
caspase-3 and cleaved poly(ADP ribose) polymerase
(PARP) (Fig. 2B, C, and Fig. S9). Consistently, knockdown
and inhibition of KDM4C increased the expression of
proapoptotic markers (Bak, Bax, and Puma) and
decreased the expression of an antiapoptotic marker (Bcl-
xL) (Fig. 2B and Fig. S4B). We conclude that KDM4C
depletion promotes apoptosis in glioblastoma cells.
KDM4C oncoprotein upregulates c-Myc gene expression
by directly binding to its promoter
c-Myc accumulates in both U87 glioblastoma cell line28
and tissues29. Before our study, Myc18 and MDM230 were
the few characterized target genes of KDM4C. KDM4C is
known to promote gene transcription by erasing
H3K9me2 marks from the target gene promoter, which is
often related to gene silencing. We examined whether
KDM4C depletion affects the expression of its target
genes in glioblastoma cells. Our results showed that the
expression levels of the KDM4C target genes c-Myc and
MDM2 significantly decreased after KDM4C knockdown
(Fig. 3A, B and Fig. S10A). Treatment of SD70 decreased
c-Myc, but not MDM2 (Fig. S10). In contrast, KDM4C
overexpression induced the expression of c-Myc in glio-
blastoma cells (Fig. S7A).
Next, to gain mechanistic insight into how KDM4C reg-
ulates the expression of its target gene, we performed ChIP
assays in U87 cells to examine whether KDM4C is bound to
the promoter regions of the c-Myc gene. The ChIP assays
showed that KDM4C was significantly enriched on the c-Myc
P2 and P3 promoters (Fig. 3C, D). In contrast, KDM4C
binding was reduced at the c-Myc promoter in SD70-treated
cells compared to that in control cells (Fig. 3D). This resulted
in more enriched H3K9me3 and less enriched H3K4me3 at
the c-Myc promoter (Fig. 3D), leading to the reduced
expression of c-Myc. c-Myc, in turn, downregulated its
known target genes CDK2, CDK4, cyclin D1, and cyclin E2
required for cell cycle control (Fig. S8). Furthermore, over-
expression of c-Myc in KDM4C-inhibited cells abolished the
reduction of its target gene expression caused by KDM4C
expression (Fig. 4A). In parallel, an analysis of GEO profiles
(GSE36245) in 35 patients with glioblastoma revealed a
positive correlation between the expression of KDM4C and
c-Myc (Fig. 3E). No statistically significant correlation was
observed between other KDM4s and c-Myc levels (Fig.
S11A). Another KDM4C target gene, MDM2, exhibited a
similar expression correlation pattern in glioblastoma
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samples (Fig. 3E). Altogether, our results suggest that
KDM4C epigenetically promotes the expression of the
oncogene c-Myc by directly binding to its promoter and
erasing H3K9me3 marks in glioblastoma cells.
KDM4C interacts with p53 via its middle domains
Studies have shown that p53 interacts with KDM4A and
KDM4C in human HCT116 colorectal cancer cells31,32.
We speculated that KDM4 might interact with p53 in
glioblastoma cells. We observed that KDM4A and
KDM4C, but not two other proteins KDM4B and
KDM4D, formed complexes with p53 at the endogenous
protein levels in U87, LN215, and SNB19 glioblastoma
cell lines (Fig. S12A, B). Next, we carried out reverse order
Co-IP experiments and confirmed that p53 forms a
complex with KDM4C. Subsequently, we conducted GST
pull-down assays to define the domains of KDM4C and
p53 that mediate their interaction. Although N-terminal
350 amino acids, which include the catalytic domain of
KDM4C, did not interact with p53, the middle portion of
KDM4C (amino acids 280–720) interacted with p53 (Fig.
S12C, E). In addition to the full-length p53, the middle
portion of p53 embracing its DNA-binding domain bound
to KDM4C in vitro (Fig. S12D, F). Altogether, these
Fig. 1 Selective inhibition of KDM4C suppresses glioblastoma cell growth and viability. A, D, H Immunoblotting of KDM4C expression in U87
and U251 cells treated. Normalized cell growth (B) and viability (C) of siCtrl and siKDM4C-treated U87 cells for 72 h. The proliferation of U87 (E) and
U251 (F) cells expressing a non-target control shRNA (shCtrl NT) or shRNA constructs targeting KDM4C (shKDM4C) was monitored for 10 days using
an IncuCyte ZOOM system. G Microscopic images and quantified colonies formed by KDM4C knockdown in U87 and U251 cells. Data present the
mean ± SD (n= 3). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. siCtrl or shCtrl NT control; Student’s t-tests.
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Fig. 2 KDM4C knockdown triggers apoptosis in glioblastoma cells. A Immunoblotting of KDM4 and histone proteins in shCtrl NT and shKDM4C
expressing U87 and U251 cells. B Immunoblotting of apoptotic markers in shCtrl NT and shKDM4C expressing U87 and U251 cells. C Apoptosis
analysis of shCtrl NT and shKDM4C expressing U87 and U251 cells as determined by Annexin V/PI double-staining and flow cytometry. Data showing
the percentage of early apoptotic and late apoptotic cells counted from dot plots. Data present the mean ± SD (n= 3). *p < 0.05, **p < 0.01, and ***p
< 0.001 vs. shCtrl NT control; Student’s t-tests.
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results demonstrate that KDM4C directly interacts
with p53.
KDM4C inhibition promotes p53 transcriptional activity
KDM4C forms complex with p53, which implies that
KDM4C might inhibit p53 transcriptional activities by
demethylating p53. Previous literature has demonstrated
that lysine methylation of p53 occurs at K370, K372,
K373, and K382 in the C-terminal regulatory domain33.
p53 Methylation at K370, K373, and K382 suppresses p53
transcriptional activity, whereas methylation at K372
facilitates its activity. We investigated whether KDM4C
activates or represses p53-dependent transcription using
p21 or Bax promoter-luciferase assay in U87 cells. Our
Fig. 3 KDM4C depletion suppresses the expression of c-Myc in glioblastoma cells. A Immunoblotting of KDM4C and its target genes in shCtrl
NT and shKDM4C expressing U87 and U251 cells. B RT-qPCR showing KDM4C and MDM2 mRNA levels in shCtrl NT and shKDM4C expressing U87
cells. mRNA expression levels were normalized to GAPDH mRNA levels. *p < 0.05 and **p < 0.01 vs. shCtrl NT control; Student’s t-tests. C Schematic
representation of the c-Myc promoter. D ChIP-qPCR analysis of KDM4C, H3K4me3, and H3K9me3 levels at the c-Myc promoter in 0.1% DMSO
(control)- and SD70-treated U87 cells. Data present the mean ± SD (n= 3). *p < 0.05 and **p < 0.01 vs. DMSO control; Student’s t-tests. E GEO analysis
of microarray dataset GSE36245 (GPL570, glioblastoma brain tumors, n= 35). Pearson’s correlation coefficient analysis was used to measure the
relationship between KDM4C and c-Myc or MDM2 mRNA levels.
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results showed that cotransfection of p53 promoted an
increase in p21 and Bax promoter activities following
KDM4C inhibition by SD70 treatment (Fig. 5A, B). This
p53-mediated stimulation was blocked by the over-
expression of KDM4C (Fig. 5C), suggesting that KDM4C
inhibits p53 function. To further confirm this result, we
examined whether direct genetic or pharmacological
inhibition of KDM4C affects the expression of the p53
target genes. We observed that KDM4C knockdown and
inhibition increased the expression of p53 target genes
CDKNA1 (p21), PUMA, BAX, and KDM4B in U87 cells
(Fig. 5D–G). Consistently, the expressions of p21, Bax,
and PUMA proteins were increased by KDM4C inhibition
(Figs. 5H and 2C). In addition, the KDM4C inhibition in
p53-depleted cells abrogated the induction of p53 apop-
totic gene expression caused by KDM4C inhibition (Fig.
4B). Moreover, the ChIP assays revealed that KDM4C
inhibition significantly increased the recruitment of p53
to the PUMA promoter in U87 cells compared to that in
control cells (Fig. 5I). These data indicate that KDM4C
regulates the transcriptional activity of p53.
KDM4C demethylates p53 at lysine 372
As KDM4C knockdown activated the expression of p53
target genes, we hypothesized that increasing the methy-
lation of p53 enhances its transcriptional activities.
Monomethylation of p53 at K372 (p53K372me1) by Set7/9
is required for the nuclear localization and stabilization of
the chromatin-bound p53 for the transcriptional activation
of target genes33. However, it remains largely unknown
whether KDM4C regulates p53K372me1. Therefore, we
determined whether KDM4C depletion increased the level
of p53K372me1. We observed that KDM4C knockdown
using shRNA and siRNA elevated the levels of
p53K372me1 as well as p53 in wt p53 harboring U87 and
A172 cells (Fig. 6A, B). Similarly, SD70 treatment also
elevated the levels of p53K372me1 and p53 in wt p53
harboring U87 and A172 cells (Fig. S13). We also con-
ducted IP to enrich p53K372me1 from whole-cell lysates
and subsequently detected them using anti-p53 antibodies.
As shown in Fig. 6, KDM4C inhibition by SD70 treatment
dramatically increased the level of p53K372me1, whereas
KDM4C overexpression produced the opposite effect in
U87 cells (Fig. 6C, D). The increased p53K372me1 levels,
in turn, promoted acetylation at the nearby C-terminal
lysine residue of p53 (K381 and K382) and phosphoryla-
tion at serine 15, resulting in the stabilization of p53
protein. While acetylation levels of p53K381 and p53K382
increased, those of p53K372 decreased in both KDM4C-
depleted and SD70-treated U87 cells (Figs. S13 and S14).
To further validate whether the stabilization of chromatin-
bound p53K372me1 increases the level of p53 on the
PUMA promoter, we also conducted ChIP assays using
anti-p53K372me1 antibodies. We observed that KDM4C
Fig. 4 Altered expression of c-Myc and p53 in KDM4C-inhibited cells rescues c-Myc and p53 target gene expressions caused by KDM4C
inhibition. A Immunoblot analysis of KDM4C, c-Myc, and its target genes in U87 cells transfected with c-Myc (0.6 μg) without or with the treatment
of SD70 (10, 20 μM). B Immunoblot analysis of KDM4C, p53, and its target genes in shCtrl NT and shp53 expressing U87 cells without or with the
treatment of SD70 (5 μM).
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inhibition indeed resulted in increased binding of
p53K372me1 on the PUMA promoter (Fig. 5I). Collec-
tively, these results suggest that KDM4C demethylates
p53K372me1 to inhibit its transcriptional activity and
proapoptotic functions.
KDM4C is required for glioblastoma tumorigenesis
To investigate whether KDM4C is involved in the
tumorigenesis of glioblastoma, we used a doxycycline-
inducible (Tet-On) KDM4C shRNA system in U87 cells.
Upon inducible KDM4C knockdown, the protein levels of
KDM4C and c-Myc were significantly decreased, whereas
the levels of p53 were increased in the doxycycline-treated
groups compared to those in the control groups (Fig. 7A).
Furthermore, the doxycycline-induced knockdown of
KDM4C resulted in significant inhibition of cell growth
and viability (Fig. S15). The clonogenic assay data revealed
that the doxycycline-induced knockdown of KDM4C
substantially reduced the colony formation of U87 cells
(Fig. 7B). We next evaluated whether KDM4C knockdown
affected tumor growth in vivo using the mouse tumor
xenograft model. Our results showed that the tumorigenic
Fig. 5 KDM4C inhibition promotes p53 transcriptional activity. A, B The activity of p21 and Bax luciferase reporter constructs in U87 cells treated
with 0.1% DMSO (control) and SD70 following transfection with p53. ***p < 0.001 vs. pcDNA control; $$$p < 0.001 vs. pcDNA-p53 group, ###p < 0.001
vs. DMSO+pcDNA-p53 group; one-way ANOVA. C The activity of a p21 luciferase reporter construct in U87 cells following transfection with p53 and
KDM4C. D–G RT-qPCR showing KDM4s, p53, and p53 target gene mRNA levels in U87 cells treated with shRNA (D and E) or SD70 (F and G). mRNA
expression levels were normalized to GAPDH mRNA levels. H Immunoblotting of KDM4C, p53, and p21 expression in U87 and U251 cells treated with
shRNA or SD70 for 24 h. I ChIP-qPCR analysis of p53 and p53K372me1 levels at the PUMA promoter in 0.1% DMSO (control) and SD70 (5 µM) treated
U87 cells. Data present the mean ± SD (n= 3). *p < 0.05 and **p < 0.01 vs. shCtrl NT or DMSO control; Student’s t-tests.
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capacity of U87 cells was hampered by the depletion of
KDM4C (Fig. 7C–E). Quantification of tumor volume and
tumor weight disclosed a significant reduction in tumor
growth in mice xenografted with doxycycline-inducible
shKDM4C U87 cells (Fig. 7C–E). These data indicate that
KDM4C is essential for the tumorigenesis of glioblastoma.
Discussion
Glioblastoma is the deadliest clinical subtype of glioma
and one of the most poorly characterized glioma at the
molecular level1. The poor understanding of this malig-
nancy has significantly limited its therapeutic manage-
ment. Although epigenetic dysregulation by KDM4C has
emerged as an important mechanism in several cancers,
the molecular mechanisms underlying the contribution of
KDM4C to cell proliferation and tumorigenesis remain to
be further elucidated in glioblastoma. In this study, we
observed that KDM4C promotes the proliferation and
tumorigenesis of glioblastoma through the activation of c-
Myc and the inactivation of p53 (Fig. 7G). These findings
demonstrate a novel role for KDM4C in controlling
glioblastoma proliferation and tumorigenesis and suggest
the potential therapeutic significance of KDM4C in
glioblastoma.
Our findings demonstrate that the histone demethylase
KDM4C is essential for the tumor progression of glio-
blastoma. To regulate this process, KDM4C engages two
distinct mechanisms; one by demethylating the histone
(H3K9me3) of target genes (e.g., c-Myc and MDM2) and
the other by targeting and demethylating a non-histone
protein, p53 (p53K372me1). KDM4C activates the
expression of the oncogenes c-Myc and MDM2 by
Fig. 6 KDM4C interacts with and demethylates p53 at K372. A, B Immunoblotting of KDM4C, p53, and p53K372me1 in U87 and U251 cells
transfected with (A) shRNA and (B) siRNA. C, D Lysates of cells treated with SD70 (20 μM) (C) or HA-KDM4C (D) were immunoprecipitated with p53
antibody followed by immunoblotting with antibodies as indicated. Ten percent of total cell lysates used in immunoprecipitation is shown as input.
The level of p53K372me1 was quantified relative to p53, and the control levels were set at 1. The asterisk indicates the expected sizes for
p53K372me1.
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Fig. 7 KDM4C regulates the proliferation and xenograft tumor growth of glioblastoma. A Immunoblotting of KDM4C, c-Myc, and p53 in U87
TetOn-KDM4C cells expressing shCtrl NT or shKDM4C. B Liquid colony formation assays of U87 TetOn-KDM4C cells expressing shCtrl NT or shKDM4C.
*p < 0.05 and **p < 0.01 vs. Dox (-) group; one-way ANOVA. C–E Xenograft assays of U87 cells with inducible expression of shCtrl NT or shKDM4C
(n= 3). C Representative U87 xenograft tumors isolated from individual animals. D Increase in tumor volume over time. E Final tumor weights of the
U87 xenografts. Data present the mean ± S.D. *p < 0.05 and **p < 0.01 vs. shCtrl NT control; one-way ANOVA. F Representative image of IHC staining
of KDM4C and c-Myc in tissues from U87 xenograft model. Scale bar, 100 μm. G Molecular model describing that KDM4C can regulate glioblastoma
proliferation and apoptosis by modulating c-Myc and p53.
Lee et al. Cell Death and Disease           (2021) 12:89 Page 12 of 14
Official journal of the Cell Death Differentiation Association
removing the repressive methylation (H3K9me3) mark,
whereas it inhibits the p53 target gene (e.g., p21, Bax, and
PUMA) expression and the p53-induced apoptosis by
demethylating p53K372me1. The C-terminal regulatory
domain of p53 is crucial for the regulation of its activity
and stability. Lysine residues of the p53 C-terminal region
are methylated at K370, K372, and K373 by histone lysine
methyltransferases (KMT)-3C, KMT1C/D, and KMT5A,
respectively34. K370me1 and K373me2 repress the tran-
scriptional activity of p53, but K372me1 enhances the
activity of p5335. Furthermore, increased levels of
p53K372me1 elevated the level of p53 acetylated at K381
and K382, which enhances the stability of p5335. Impor-
tantly, our results demonstrate that KDM4C inhibition
enhances the functional activity and stability of p53 by
inducing the monomethylation of p53K372, acetylation of
p53K381/382, and phosphorylation of p53S15. Hence, our
results suggest that p53 at K372me1 is a target site
for KDM4C.
In the Cancer Genome Atlas (TCGA) glioblastoma data-
base, Myc expression was upregulated in all glioblastoma
subtypes relative to that in the normal human cerebrum29. In
addition, Myc expression was more increased in recurrent
glioblastoma compared to that in newly diagnosed glio-
blastoma29. Although c-Myc is infrequently mutated in
glioblastoma, increases in its copy number and nuclear
staining have been investigated36. The expression of Myc
core signature37 correlates with that of the gene signature in
glioblastoma tumorigenicity29,38. These results support a
relationship between Myc expression and tumorigenicity.
Interestingly, several studies have demonstrated that glio-
blastoma cells overexpress several KDM genes, and some
KDMs are involved in the Myc-mediated tumorigenesis. c-
Myc39 and N-Myc40 interact with lysine-specific demethylase
1 (LSD1/KDM1A) and promote its recruitment to the E-box
chromatin. Furthermore, KDM1A is a cofactor of the
repressive function of N-Myc in neuroblastoma. KDM1A
also decreases H3K4me3 at the c-Myc locus and reduces the
expression of Myc29 as well as its target genes in glioblastoma
cells. Recently, Nagasaka et al.41 demonstrated that KDM1A
is a direct target of c-Myc. Our findings revealed that
KDM4C directly binds to the c-Myc P2 and P3 promoters
and induces its expression. KDM4C and c-Myc expressions
were positively correlated, whereas those of KDM4A,
KDM4B, and KDM4D did not correlate with c-Myc in
glioblastoma. Also, KDM4C has no effects on N-Myc
expression in glioblastoma (data not shown), and the corre-
lation of the expression between the two genes has not yet
been reported. These findings indicate that KDM1A and
KDM4C have opposite functions on c-Myc expression and
contribute to fine-tuning its expression; KDM1A represses c-
Myc expression by demethylating the active marker
H3K4me2/me1, whereas KDM4C activates its expression by
demethylating the repressive marker H3K9me3/me2. Our
observation that the inhibition of KDM4C leads to decreased
c-Myc expression and increased expression of p53, p21, and
PUMA suggests that KDM4C is a novel factor of c-Myc
signaling in glioblastoma. Such oncogenic function of
KDM4C is caused due to the dissociation of the epigenetic
reader heterochromatin protein 1 (HP1) from the target gene
promoters, including c-Myc, thereby reducing H3K9me3
levels and losing heterochromatin to activate oncogenes and
increase genomic instability12. c-Myc suppresses the p53
target gene p2142 and PUMA43 expression by directly bind-
ing to the E-box promoter, whereas p53 binds to the c-Myc
NHE promoter and represses its expression44. Therefore, the
reduction of c-Myc by KDM4C inhibition increases p21 and
PUMA levels, together with p53 activation. Consequently,
KDM4C inhibition might synergistically increase the levels of
p21 and PUMA expression. Because of glioblastoma’s
addiction to Myc signaling45,46, Myc proteins are considered
as suitable therapeutic targets. However, Myc protein has
long been considered as an undruggable cancer target, and a
clinically available direct inhibitor of Myc has not been
developed due to the lack of deep surface-binding pockets47.
As an alternative strategy, Myc inhibition can be achieved by
epigenetic silencing of Myc genes (e.g., bromodomain inhi-
bitor) or by blocking the signaling pathways downstream of
the Myc transcription factor. These results suggest that the
KDM4C-cMyc-p53 signaling cascade is a novel mechanism
underlying the progression of glioblastoma. Therefore, tar-
geting KDM4C as an indirect Myc-targeting approach may
be a promising novel cancer therapy for glioblastoma.
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